PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 171 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,215 | +61.6% | 72,830 | +167.5% | 0.06% | +72.7% |
| Q2 2023 | $752 | +55.4% | 27,230 | +29.3% | 0.03% | +43.5% |
| Q1 2023 | $484 | -47.3% | 21,060 | -75.0% | 0.02% | -54.9% |
| Q4 2022 | $918 | -99.8% | 84,172 | +18.7% | 0.05% | +41.7% |
| Q3 2022 | $598,000 | -14.2% | 70,932 | -19.5% | 0.04% | -30.8% |
| Q2 2022 | $697,000 | +21.0% | 88,097 | +262.3% | 0.05% | +36.8% |
| Q1 2022 | $576,000 | +206.4% | 24,317 | +56.7% | 0.04% | -44.9% |
| Q2 2019 | $188,000 | +42.4% | 15,517 | +48.0% | 0.07% | -8.0% |
| Q1 2019 | $132,000 | +40.4% | 10,487 | -25.3% | 0.08% | +188.5% |
| Q4 2018 | $94,000 | -79.5% | 14,041 | -68.4% | 0.03% | -73.7% |
| Q3 2018 | $458,000 | +31.2% | 44,477 | -14.3% | 0.10% | +37.5% |
| Q2 2018 | $349,000 | – | 51,907 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $26,721 | 7.77% |
| Bain Capital Life Sciences Investors, LLC | 2,364,410 | $25,796 | 2.88% |
| Sio Capital Management, LLC | 434,635 | $4,741,868 | 1.75% |
| Tri Locum Partners LP | 199,500 | $2,177,000 | 0.88% |
| Kynam Capital Management, LP | 520,922 | $5,683,259 | 0.87% |
| RTW INVESTMENTS, LP | 3,591,986 | $39,188,567 | 0.80% |
| Madison Avenue Partners, LP | 406,593 | $4,435,930 | 0.79% |
| Deep Track Capital, LP | 871,493 | $9,507,989 | 0.40% |
| Soleus Capital Management, L.P. | 236,000 | $2,574,760 | 0.37% |
| BRAIDWELL LP | 927,800 | $10,122,298 | 0.34% |